2-C-Methyl-D-Ribono-1,4-Lactone

492-30-8

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-o≈riented and realizes industrial development through R&∞;D innovation and technology transformation.

key word:

technology Pharmaceutical

Category:

Intermediate

Consulting
Related

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industr∑y finance platform company integrating pharmaceutical, intelligent m≥edical, bio pharmaceutical R&D, industrial production and sale©s.

The chemical reactions involved in the existing products include Foucault rea€ction, nitration reaction, sulfonation reaction, hydrεogenation reaction, fluorination reaction, chlorination reaction,ε bromination reaction, diazotization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor devεeloped by Merck. In October 2006, Sitagliptin phosphate Januvia was approved by FDA as t§he first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The chσaracteristics of this drug are that it can stimulate insu​lin secretion while reducing hunger without causing weight gain. Hypoglycemia and •edema will not occur, and it is suitable for diabetic patientsΩ with poor blood glucose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceut‍ical enterprise that is market-oriented and realizes industrial development through R&D innovation¥ and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen iσs one of the most important products for the treatment of arthritis. It is we¥ll tolerated and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists.> In clinical application, it has good therapeutic effect on a∏topic asthma and other types of bronchial asthma, and the market prospect is huge. In the↕ major category of asthma drugs, leukotriene receptor antagonists have the fastest growi×ng market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orie✘nted and realizes industrial development through R&D innovation and tec®hnology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the second drug approved by FDA fo±r Alzheimer's disease in the United States. Its treatment reaches the target dose and has πlow toxic and side effects. It has been widely recognized by our medical community, and good tole&rance is its biggest advantage. In October 1999, Don≠epezil was launched in China under the trade name "Aricept", which is the main chemica$l drug against Alzheimer's disease. At present, CFDA has ÷approved a number of domestic enterprises to produce donepezil preparations, the mai♣n dosage forms are tablets, capsules, dispersive tablets, oral disintegrating t ablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb/Pfizer↔), a direct oral factor Xa inhibitor, was approved f"or use in the 27 EU member states. The world's first drug approved to prevent venous th↔romboembolism (VTE) in adult patients undergoing elective hip or knee rep lacement. From June 2019 to June 2020, the annual sales of apixaba'n products overseas reached about $15.4 billion, with a year-on-year growth of nearly 32%, and t¶he API consumption reached about 23,960 kg, with a y☆ear-on-year growth of about 28%. Compared with its main competitor, Rivaroxaban, the drug's annual ®overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmλaceutical enterprise that is market-oriented and realizes industrial development through R&D innovaδtion and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Gen$zyme. On December 29, 2004, it was approved by FDA for the treatment of refractory or re¥lapsed acute lymphoblastic leukemia (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceu₹tical enterprise that is market-oriented and realizes industrial development thro‍ugh R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you neγed other services, E-mail: 2880705932@qq.com
Submit

Copyright © 2022 Anhui Union Pharmaceuticals Technology Co., Ltd.